ReviewMolecules (Basel, Switzerland)2026
Electrochemical Lateral Flow Platforms: Pioneering the Future of Rapid Testing.
Review in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transport-Reaction-Signal Coupling in Lateral Flow Assays for Next-Generation Point-of-Care Diagnostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The increasing demand for advanced diagnostic technologies has positioned biosensor platforms as powerful alternatives to conventional analytical methods. Among them, lateral flow platforms (LFPs) are widely used for their speed, simplicity, and low cost. However, their limited sensitivity and lack of quantitative precision have spurred the development of enhanced systems incorporating electrochemical detection. Electrochemical biosensors offer significant advantages, including high sensitivity, excellent selectivity, and ease of miniaturization, which make them especially suitable for point-of-care testing (POCT). To address the limitations of traditional colorimetric LFPs, several strategies have been employed, such as the incorporation of nanomaterials, enzymatic amplification, and signal-enhancing labels. A particularly promising innovation is the direct integration of electrodes into LFPs, enabling real-time electrochemical readouts and enhanced analytical accuracy. Despite their potential, challenges persist, including manufacturing complexity, a lack of standardized protocols, and difficulties in scaling production for widespread adoption. Continued progress in developing hybrid platforms that combine lateral flow technology with electrochemical detection is crucial for expanding diagnostic applications in healthcare, environmental monitoring, and food safety. This work explores recent advances in electrochemical LFPs, reviewing current methodologies while discussing their advantages, limitations, and the future directions necessary to facilitate broader implementation and improve global diagnostic accessibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.